PWA
KYTX icon

Physician Wealth Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Physician Wealth Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-420
Closed -$811 – 2004
2025
Q1 		$811 Buy
+420
New +$1.24K ﹤0.01% 1227

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Physician Wealth Advisors's KYTX Position: Q2 2025 in Review

Physician Wealth Advisors sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 420 shares — an estimated $811 sold.

Physician Wealth Advisors first reported a position in KYTX in Q1 2025 and held it in 1 quarter. The position peaked at $811 in Q1 2025. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Physician Wealth Advisors reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 420 Kyverna Therapeutics shares in Q2 2025, an estimated $811.
  • Physician Wealth Advisors first reported a position in Kyverna Therapeutics in Q1 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's Kyverna Therapeutics position peaked at $811 in Q1 2025.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Physician Wealth Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.